Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: A phase II study

Dermatology

Volumn 217, Issue 2, 2008, Pages 107-113

  Buckley, Colin ^a   Hoffmann, Vibeke ^b   Shapiro, Jerry ^c   Saari, Seppo ^d   Cambazard, Frederic ^e   Milsgaard, Mette ^b  

^a WATERFORD REGIONAL HOSPITAL   (Ireland)

^b LEO PHARMA A S   (Denmark)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d Medical Reception Centre   (Finland)

^e HÔPITAL NORD   (France)

Author keywords

Betamethasone dipropionate plus calcipotriol; Phase II study; Scalp formulation; Scalp psoriasis, topical treatment

Indexed keywords

BETAMETHASONE DIPROPIONATE; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; INFECTION; INFESTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; SCALP; SCORING SYSTEM; SKIN DISEASE; SUBCUTANEOUS TISSUE DISEASE; TREATMENT DURATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADULT; ANTI-INFLAMMATORY AGENTS; BETAMETHASONE; CALCITRIOL; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PATIENT SATISFACTION; PROBABILITY; PROSPECTIVE STUDIES; PSORIASIS; REFERENCE VALUES; RISK ASSESSMENT; SCALP DERMATOSES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 49649083588     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000130425     Document Type: Article

References (26)

1. Farber EM, Nall ML: The natural history of psoriasis in 5,600 patients. Dermatologica 1974;148:1-18.
2. Poyner TF, Fell PJ: A survey of patients with plaque psoriasis who had not consulted their doctor in the past year. Br J Clin Res 1995;6:201-207.
3. van de Kerkhof PCM, Steegers-Theunissen RPM, Kuipers MV: Evaluation of topical drug treatment in psoriasis. Dermatology 1998;197:31-36.
4. van de Kerkhof PCM, de Hoop D, de Korte J, Kuipers MV: Scalp psoriasis, clinical presentations and therapeutic management. Dermatology 1998;197:326-334.
5. Farber EM, Bright RD, Nall ML: Psoriasis: a questionnaire survey of 2,144 patients. Arch Dermatol 1968;98:248-259.
6. Feldman SR, Housman TS: Patient's vehicle preference for corticosteroid treatments of scalp psoriasis. Am J Clin Dermatol 2003;4:221-224.
7. Berth-Jones J, Chu AC, Dodd WA, Ganpule M, Griffiths WA, Haydey RP, Klaber MR, Murray SJ, Rogers S, Jurgensen HJ: A multicentre, parallel-group comparison of calcipotriol ointment and short-contact dithranol therapy in chronic plaque psoriasis. Br J Dermatol 1992;127:266-271.
8. Tham SN, Lim KC, Cheong WK: A comparative study of calcipotriol ointment and tar in chronic plaque psoriasis. Br J Dermatol 1994;131:673-677.
9. Cunliffe WJ, Berth-Jones J, Claudy A, Fairiss G, Goldin D, Gratton D: Comparative study of calcipotriol (MC 903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris. J Am Acad Dermatol 1992;26:736-743.
10. Kragballe K, Gjertsen BT, de Hoop D, Karlsmark T, van de Kerkhof PCM, Larko O, Nieboer C, Roed-Petersen J, Strand A, Tikjob G: Double-blind right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet 1991;337:193-196.
11. Ramsay CA, Berth-Jones J, Brundin G, Cunliffe WJ, Dubertret L, van de Kerkhof PCM, Menne T, Wegmann E: Long-term use of topical calcipotriol in chronic plaque psoriasis. Dermatology 1994;189:260-264.
12. Ellis JP, Griffiths WAD, Klaber MR: Long-term treatment of chronic plaque psoriasis with calcipotriol ointment in patients unresponsive to short contact dithranol. Eur J Clin Res 1995;7:247-257.
13. Green C, Ganpule M, Harris D, Kavanagh G, Kennedy C, Mallett R, Rustin M, Downes N: Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC903) in the treatment of psoriasis of the scalp. Br J Dermatol 1994;130:483-487.
14. Thaçi D, Daiber W, Boehncke WH, Kaufmann R: Calcipotriol solution for the treatment of scalp psoriasis: evaluation of efficacy, safety and acceptance in 3,396 patients. Dermatology 2001;203:153-156.
15. Barnes L, Altmeyer P, Forstrom L, Stenstrom MH: Long-term treatment of psoriasis with calcipotriol scalp solution and cream. Eur J Dermatol 2000;10:199-204.
16. Hovding G: Treatment of psoriasis of the scalp with betamethasone 17,21-dipropionate plus salicylic acid lotion ('Diprosalic'). Pharmatherapeutica 1981;3:61-66.
17. Katz HI, Lindholm JS, Weiss JS, Shavin JS, Morman M, Bressinck R, Cornell R, Pariser DM, Pariser RJ, Weng W, Samsom C: Efficacy and safety of twice-daily augmented betamethasone dipropionate lotion versus clobetasol propionate solution in patients with moderate-to-severe scalp psoriasis. Clin Ther 1995;17:390-401.
18. Kragballe K, Austad J, Barnes L, Bibby A, de la Brassinne M, Cambazard F, Fleming C, Heikkila H, Jolliffe D, Peyri J, Svensson A, Toole J, Wozel G: A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. Br J Dermatol 2006;154:1155-1160.
19. Kaufmann R, Bibby AJ, Bissonnette R, Cambazard F, Chu AC, Decroix J, Douglas WS, Lowson D, Mascaro JM, Murphy GM, Stymne B: A new calcipotriol/betamethasone formulation is a highly effective once-daily treatment for psoriasis vulgaris. Dermatology 2002;205:389-393.
20. Papp KA, Guenther L, Boyden B, Grønhøj Larsen F, Harvima RJ, Guilhou JJ, Kaufmann R, Rogers S, van de Kerkhof PC, Hanssen LI, Tegner E, Burg G, Talbot D, Chu A: Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol 2003;48:48-54.
21. Douglas WS, Poulin Y, Decroix J, Ortonne JP, Mrowietz U, Gulliver W, Krogstad AL, Larsen FG, Iglesias L, Buckley C, Bibby AJ: A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol 2002;82:131-135.
22. Guenther L, van de Kerkhof PCM, Snellman E, Kragballe K, Chu AC, Tegner E, Garcia-Diez A, Springborg J: Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol 2002;147:316-323.
23. Kragballe K, Nørrelund KL, Lui H, Ortonne JP, Wozel G, Uurasmaa T, Fleming C, Estebaranz JL, Hanssen LI, Persson LM: Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol 2004;150:1167-1173.
24. van de Kerkhof PC, Wasel N, Kragballe K, Cambazard F, Murray S: A two-compound product containing calcipotriol and betamethasone dipropionate provides rapid, effective treatment of psoriasis vulgaris regardless of baseline disease severity. Dermatology 2005;210:294-299.
25. Augustin M, Peeters P, Radtke M, Moehling U, Lapp C. Cost-effectiveness model of topical treatment of mild to moderate psoriasis vulgaris in Germany: a comparison of calcipotriol/betamethasone (Daivobet®/Dovobet®/ Taclonex®) once daily and a morning/evening non-fix combination of calcipotriol and betamethasone. Dermatology 2007;215:219-228.
26. Peeters P, Ortonne JP, Sitbon R, Guignard E: Cost-effectiveness of once-daily treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol in the treatment of psoriasis vulgaris. Dermatology 2005;211:139-145.